World Healthcare Report
SEE OTHER BRANDS

Keeping up with healthcare and wellness news from the world

AgelessRx Introduces Tadalafil Daily in Continued Pursuit of Healthspan Innovation

ANN ARBOR, Mich., June 05, 2025 /BUSINESS WIRE/ --

AgelessRx, a pioneer in longevity and telehealth solutions, announces the launch of its newest offering: Tadalafil Daily, a clinician-directed, low-dose, daily version of a well-known PDE5 inhibitor.

Commonly known for its FDA-approved treatment of erectile dysfunction (ED) and pulmonary hypertension-related symptoms, Tadalafil is a PDE5 inhibitor that works by enhancing cGMP signaling, a molecule that is essential in promoting circulation and relaxing blood vessels to promote healthy circulation throughout the body.

Cardiovascular disease is the leading cause of death worldwide and costs over $400 billion in medical spending and indirect costs. While Tadalafil is not indicated for cardiovascular disease, evidence continues to grow in vascular biology and the role of endothelial function in overall health.

"Cardiovascular disease is responsible for 1 in 3 deaths every year, yet much of our healthcare system waits until risk becomes reality. We're working to shift that approach. Prevention isn’t just a concept; it’s a clinical priority," said Dr. Stefanie Morgan PhD, Vice President of Applied Sciences. "By focusing on early, evidence-based interventions that support circulatory and endothelial health, we’re building a model of care that looks ahead at not just what’s treatable, but at what’s possible when we act sooner."

The global cardiovascular therapeutics market is valued to exceed $207 billion by 2033, driven by aging populations and an increasing demand for preventative health strategies. Emerging evidence is revealing the potential long-term effects of promoting healthy circulation, blood flow, and vascular function in reducing cardiovascular disease.

Circulatory health plays a vital role in delivering oxygen and nutrients to organs throughout the body, clearing waste and maintaining cellular health. Research continues to explore how daily support with PDE5 inhibitors may contribute to:

  • Improved vascular tone and healthy circulation
  • Enhanced oxygen and nutrient delivery to vital organs
  • Support for overall cardiovascular and endothelial health
  • Maintenance of healthy inflammatory balance

The new treatment offering reflects AgelessRx’s core mission to make longevity-focused care accessible, evidence-driven, and rooted in prevention. The treatment is available to eligible patients following medical evaluation and clinician oversight.

For additional information about AgelessRx and longevity-promoting treatments, please visit agelessrx.com.

About AgelessRx

AgelessRx is at the forefront of the longevity revolution, offering clinically validated cutting-edge solutions and preventive treatments aimed at extending life expectancy and enhancing quality of life. AgelessRx also continues to advance the field of longevity science by conducting ongoing research and clinical trials. Through its online platform, AgelessRx provides easy access to innovative healthcare services, with an emphasis on customer satisfaction, affordability, and the pursuit of a future where extended healthspan is a reality for everyone. Follow AgelessRx on Instagram, X, and Facebook.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service